Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2604-2613

  Hammond, Lisa A ^a   Eckardt, John R ^a   Baker, Sharyn D ^a   Gail Eckhardt, S ^a   Dugan, Margaret ^a   Forral, Kelly ^a   Reidenberg, Pascale ^a   Statkevich, Paul ^a   Weiss, Geoffrey R ^a   Rinaldi, David A ^a   Von Hoff, Daniel D ^a   Rowinsky, Eric K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 0032812622     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2604     Document Type: Article

References (32)

1. Newlands ES, Blackledge GRP, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291, 1992
2. O'Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: A new oral cytotoxic chemotherapy agent with promising activity against primary brain tumors. Eur J Cancer 29A:940-942, 1993
3. Nicholson HS, Krailo M, Seibel NL, et al: Phase I study of temozolomide (TEM) in children and adolescents: A report from the Children's Cancer Group (CCG). Proc Am Soc Clin Oncol 16:214, 1997 (abstr 751)
4. Bleehan NM, Newlands ES, Lee SM, et al: Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913, 1995
5. Pearson ADJ, Estlin EJ, Lashford L, et al: Phase I study of temozolomide in pediatric patients with advanced cancer. Proc Am Soc Clin Oncol 15:490, 1996 (abstr 1564)
6. Brada M, Moore S, Judson I, et al: A phase I study of SCH 52365 (temozolomide) in adult patients with advanced cancer. Proc Am Soc Clin Oncol 14:470, 1995 (abstr 154)
7. Woll PJ, Crowther D, Johnson PWM, et al: Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 72:183-184, 1995
8. Gibson NW, Hickman JA, Erickson LD: Effects of the antitumor agent 8-carbamoyl-3-(2-chloroethyl) imidazo (5, 1-d)1, 2, 3, 5-tetrazin-4(3 H)-one on the DNA of mouse L1210 cells. Cancer Res 44:1767-1771, 1984
9. Gibson NW, Hickman JA, Erickson LD: DNA crosslinking and cytotoxicity in normal and transferred human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)-imidazo (5-1-d),1, 2, 3, 5-tetrazin-4 (3 H)-one. Cancer Res 44:1772-1775, 1985
10. Newlands ES, Blackledge G, Slack JA, et al: Phase I clinical trial of mitozolomide. Cancer Treat Rep 69:7-8, 1985
11. Herait P, Rougier P, Oliviera J, et al: Phase II study of mitozolomide (M&B39565) in colorectal and breast cancer. Invest New Drugs 6:323-325, 1988
12. Harding M, Northcott D, Smyth J, et al: Short communication in: Phase II evaluation of mitozolomide in ovarian cancer. Br J Cancer 57:113-114, 1988
13. Stevens MFG, Hickman JA, Stone R, et al: Antitumor imidazotetrazines: I. Synthesis and chemistry of 8-carbamoyl-3(2-chloroethyl) imidazo (5, 1, d)-1, 2, 3, 5-tetrazin-4(3H)-one, a novel broad spectrum antitumour agent. J Med Chem 27:196-201, 1984
14. Denny BJ, Wheelhouse RT, Stevens MFG, et al: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045-9051, 1994
15. Stevens MFG, Hickman JA, Langdon SP, et al: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846, 1987
16. Mizuno NS, Decker RW: Alteration of DNA by 5-(3-methyl-1-triazeno) imidazole-4-carboxamide (NSC-407347). Biochem Pharmacol 25:2643-2647, 1976
17. 6-benzylguanine: A comparative study in vitro. Br J Cancer 73:482-490, 1996
18. Plowman J, Waud WR, Koutsoukos AD, et al: Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumor xenografts and synergism with 1,3-bis (2-chloroethyl)-1-nitrosourea. Cancer Res 54:3793-3799, 1994
19. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67:1299-1302, 1993
20. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 47:4884-4889, 1987
21. 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:299-308, 1999
22. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:13, 1976
23. National Cancer Institute: Guidelines for Reporting of Adverse Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
24. Shen F, Decosterd LA, Gander M: Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr 667:291-300, 1995
25. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Marcel Dekker, 1982, pp 409-417
26. Dhodapkar M, Rubin J, Reid JM, et al: Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3:1093-1100, 1997
27. Reid JM, Stevens DC, Rubin J, et al: Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3:2393-2398, 1997
28. Baker SD, Statkevich P, Rowinsky E, et al: Pharmacokinetics (PK) and pharmacodynamics (PD) of temozolomide (TEM) administered as a single oral dose. Pharm Res 13:5487, 1996 (abstr)
29. Liu L, Markowitz S, Gerson SL: Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis (2-chloroethyl) nitrosourea. Cancer Res 56:5375-5379, 1996
30. 6 alkylguanine DNA transferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69:452-456, 1994
31. 6-benzylguanine increases the sensitivity of human primary bone cells to the cytotoxic effects of temozolomide. Exp Hematol 23:112-116, 1995
32. 6 methyl-DNA methyl-transferase in human normal and tumour tissue from brain, lung, and ovary. Cancer Res 51:4131 -4134, 1991